Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient

Katgi A., Ataca P., Kahraman S., Piskin O., Ozcan M. A., DEMİRKAN F., ...More

BLOOD COAGULATION & FIBRINOLYSIS, vol.23, no.1, pp.69-70, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1097/mbc.0b013e32834b8267
  • Journal Name: BLOOD COAGULATION & FIBRINOLYSIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.69-70
  • Keywords: acquired hemophilia, recombinant factor VIIa, thromboembolic attack, INHIBITORS, METAANALYSIS, THERAPY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a case that presented with extensive cutaneous and mucosal bleedings due to factor VIII inhibitors and was treated successfully with rFVIIa and steroid therapy, but was complicated with a life-threatening thromboembolic attack during follow-up. Blood Coagul Fibrinolysis 23:69-70 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.